Peri-Operative Magnesium Infusion to Prevent Atrial Fibrillation Evaluated.
Status:
Recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
Post-operative atrial fibrillation (POAF) is commonly observed in patients post cardiac
surgery without a previous history of atrial fibrillation (AF) or other arrythmias. It's
associated with significant postoperative complications including infection, bleeding
reoperation, increased hospital length of stay (LOHS) and mortality. Magnesium has been
identified as a potentially interesting compound with easy access and low toxicity.
Hypomagnesemia has been observed frequently immediately after cardiac surgery. Both reduction
of abnormal atomicity of atrial myocardium and prolongation of the atrial refractory period
caused by administration of magnesium may prevent AF. The POMPAE trial will analyse the
effectiveness of MgSO4 versus placebo (double blind randomized trial) in the prevention of
POAF after cardiac surgery.